Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.40 |
| ▸ | CES2 | O00748 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8598488 | 0.91 | ESR1 (0.52) | CES2ALDH1A1ESR1ESR2CYP3A4 | |
| SCHEMBL2761265 | 0.84 | CES2 (0.55) | CES1CES2ALDH1A1CYP3A4KCNK9 | |
| SCHEMBL14856629 | 0.84 | CES2 (0.55) | CES1CES2ALDH1A1CYP3A4KCNK9 | |
| SCHEMBL719395 | 0.84 | CES2 (0.55) | CES1CES2ALDH1A1CYP3A4KCNK9 | |
| SCHEMBL8823207 | 0.84 | CES2 (0.55) | CES1CES2ALDH1A1CYP3A4KCNK9 | |
| SCHEMBL6682499 | 0.84 | CES2 (0.55) | CES1CES2ALDH1A1CYP3A4KCNK9 | |
| SCHEMBL8216935 | 0.83 | L3MBTL1 (0.53) | ALDH1A1KCNK9MAPTTDP1L3MBTL1 | |
| SCHEMBL10762267 | 0.82 | CES2 (0.52) | CES1CES2ALDH1A1CYP3A4KCNK9 | |
| SCHEMBL9846771 | 0.81 | KCNN4 (0.50) | ALDH1A1ESR1ESR2CYP3A4TSHR | |
| SCHEMBL10597514 | 0.80 | CYP3A4 (0.43) | CES1CES2ALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 978 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-09-21 | — | — | US | claimed |
| EP-3560937-B1 | METHODS OF PREPARING 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS AND DIAGNOSTIC METHODS THEREWITH | CANCER TARGETED TECH LLC (US) | 2022-12-28 | — | — | EP | claimed |
| WO-2021222783-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2021-11-04 | — | — | WO | claimed |
| EP-3036227-B1 | PROCESS FOR PREPARING A COMPOUND | GENENTECH INC (US) | 2020-01-08 | — | — | EP | claimed |
| EP-2970345-B1 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS | CANCER TARGETED TECH LLC (US) | 2019-06-19 | — | — | EP | claimed |
| CN-106083807-B | 4- amino -5- biphenyl -4- base -2- methylol -2- methvl-pentanoic acid compounds and preparation method thereof | 施万生物制药研发IP有限责任公司 | 2018-09-11 | — | — | CN | claimed |
| WO-2018150386-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF BORONIC ACID ESTERS | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2018-08-23 | — | — | WO | claimed |
| CN-106083807-A | 4 amino 5 biphenyl 4 base 2 methylol 2 methylvaleric acid compounds and preparation method thereof | 施万生物制药研发IP有限责任公司 | 2016-11-09 | — | — | CN | claimed |
| US-20130324459-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-12-05 | — | — | US | claimed |
| EP-2188298-B1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2013-09-18 | — | — | EP | claimed |
| EP-1745064-A2 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | Proteolix, Inc. (US) | 2007-01-24 | — | — | EP | claimed |
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | DART MICHAEL J | 2006-12-21 | — | — | US | claimed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | claimed |
| WO-2006031814-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | COMBIMATRIX CORPORATION (US) | 2006-03-23 | — | — | WO | claimed |
| US-20060054511-A1 | Electrochemical deblocking using a hydrazine derivative | CUSTOMARRAY, INC. | 2006-03-16 | — | — | US | claimed |
| WO-2005105827-A2 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050245435-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2005-11-03 | — | — | US | claimed |
| US-6841559-B1 | Pyridinones to treat and prevent bacterial infections | WASHINGTON UNIVERSITY OF ST. LOUIS (US) | 2005-01-11 | — | — | US | claimed |
| US-5420149-A | Hypotensive agents and artheriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-30 | — | — | US | claimed |
| US-5352687-A | Hypotensive agents | BAYER AKTIENGESELLSCHAFT (DE) | 1994-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324459-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | CES1 934/4885CES2 2259/4885ALDH1A1 2975/4885 |
| US-20050245435-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | CES1 1427/4885CES2 3063/4885ALDH1A1 3506/4885 |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | LSS, DHPS, CYP51A1 | CES1 1016/4885CES2 2017/4885ALDH1A1 1435/4885 |
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHAT, CHRNA6 | CES1 457/4885CES2 54/4885ALDH1A1 356/4885 |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | TM9SF4, TM9SF2, TM9SF3 | CES1 1629/4885CES2 2828/4885ALDH1A1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.